公司公告汇总 公司代码603172，股票简称万丰股份，董事会秘书卢枫青，证券事务代表张潮军。2025年半年度报告未 经审计，公司不进行利润分配和公积金转增股本。截至报告期末，公司总资产14.68亿元，净资产10.74 亿元，加权平均净资产收益率2.38%，基本每股收益0.19元。前十大股东中，绍兴御丰企业管理有限公 司持股43.71%，俞杏英持股11.25%，两者与绍兴天扬投资为一致行动人。公司披露2025年上半年分散 染料销售收入2.43亿元，滤饼销售收入3037.65万元，分散染料平均售价同比下降0.31%，滤饼同比下降 3.12%。主要原材料氢溴酸单价上涨25.08%。募集资金账户余额1640万元，部分募投项目延期，"年产1 万吨分散染料技改提升项目"延期至2025年12月，"研发中心建设项目"延期至2026年12月。董事会及监 事会均审议通过半年度报告及相关议案。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：万丰股份2025年中报归母净利润同比增长91.69%。 股本股东变化：截至2025年8月20日股东户 ...

截至2025年8月29日收盘，振德医疗（603301）报收于24.3元，较上周的24.31元下跌0.04%。本周，振 德医疗8月25日盘中最高价报24.41元。8月28日盘中最低价报23.08元。振德医疗当前最新总市值64.75亿 元，在医疗器械板块市值排名55/126，在两市A股市值排名2698/5152。 本周关注点 业绩披露要点 振德医疗2025年中报显示，公司主营收入21.0亿元，同比上升2.83%；归母净利润1.28亿元，同比下降 20.7%；扣非净利润1.18亿元，同比下降26.97%；其中2025年第二季度，公司单季度主营收入11.09亿 元，同比上升2.79%；单季度归母净利润7652.23万元，同比下降12.76%；单季度扣非净利润7042.83万 元，同比下降18.91%；负债率29.46%，投资收益163.13万元，财务费用1454.23万元，毛利率34.19%。 公司公告汇总 振德医疗用品股份有限公司将于2025年9月11日（星期四）10:00-11:00召开2025年半年度业绩说明会， 会议地点为上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com ...

截至2025年8月29日收盘，安杰思（688581）报收于75.89元，较上周的83.59元下跌9.21%。本周，安杰 思8月25日盘中最高价报84.8元。8月28日盘中最低价报75.03元。安杰思当前最新总市值61.45亿元，在 医疗器械板块市值排名59/126，在两市A股市值排名2814/5152。 本周关注点 中信证券股份有限公司发布杭州安杰思医学科技股份有限公司2025年半年度持续督导跟踪报告，履行持 续督导职责。持续督导期间，未发现公司存在重大问题或重大违规事项。公司面临核心竞争力风险、经 营风险、贸易摩擦及汇率波动风险、行业政策变动风险、宏观环境风险等。2025年上半年，公司营业收 入同比增长14.56%，利润总额同比增长2.78%，归属于上市公司股东的净利润同比增长1.26%，经营活 动产生的现金流量净额同比下降34.90%。研发投入同比增长33.29%，占营业收入比例增加1.60个百分 点。公司未开展新增业务，募集资金使用合规，控股股东及高管持股未发生变化。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自公司公 ...

Core Viewpoint - The company, Times Electric, has shown significant growth in its financial performance for the first half of 2025, with increases in revenue and net profit, alongside a reduction in the number of shareholders and a planned cash dividend distribution [2][4]. Financial Performance - The company's main revenue for the first half of 2025 reached 12.214 billion yuan, representing a year-on-year increase of 17.95% [2][4]. - The net profit attributable to shareholders was 1.672 billion yuan, up 12.93% year-on-year [2][4]. - The net profit excluding non-recurring items was 1.588 billion yuan, reflecting a substantial increase of 37.04% year-on-year [2]. - In Q2 2025, the company achieved a single-quarter revenue of 7.677 billion yuan, a year-on-year increase of 19.88% [2]. - The single-quarter net profit attributable to shareholders was 1.04 billion yuan, up 12.63% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 991 million yuan, showing a significant increase of 42.02% year-on-year [2]. - The company's debt ratio stood at 36.39%, with investment income recorded at -12.4073 million yuan and financial expenses at -178 million yuan [2]. Shareholder Changes - As of July 31, 2025, the number of shareholders was 20,600, a decrease of 920, or 4.28%, from July 18, 2025 [1][4]. - The average number of shares held per shareholder increased from 40,400 to 42,200 shares, with an average holding value of 1.8466 million yuan [1]. Dividend Announcement - The company plans to distribute a cash dividend of 4.40 yuan (including tax) for every 10 shares to all shareholders [3][4]. - As of June 30, 2025, the total share capital was 1,357,948,412 shares, leading to a total cash dividend distribution of approximately 597.5 million yuan, which accounts for 35.75% of the net profit attributable to shareholders for the first half of 2025 [3].

Group 1 - JinkoSolar's stock price increased by 3.75% this week, closing at 5.54 yuan, with a market cap of 55.429 billion yuan, ranking 5th in the photovoltaic equipment sector [1] - The company provided a total guarantee of 460 million yuan for its subsidiaries to secure financing from financial institutions, with no overdue external guarantees reported [1] - The total amount of guarantees provided by JinkoSolar to its controlling subsidiaries reached 44.929 billion yuan, accounting for 139.06% of the latest audited net assets and 37.10% of total assets [1] Group 2 - JinkoSolar (Feidong) Co., Ltd. applied for a comprehensive credit limit of up to 100 million yuan from Guangfa Bank, with a credit term not exceeding one year [3] - JinkoSolar Middle East DMCC applied for a comprehensive credit limit of up to 360 million yuan (or equivalent foreign currency) from Industrial Bank, with a credit term not exceeding one year [3]

Core Viewpoint - Zhendemedical (603301) has shown a positive performance with a stock price increase of 1.46% this week, closing at 19.42 yuan, reflecting a stable growth trend in the medical device sector [1] Company Announcements - Zhendemedical will hold its 2024 Annual General Meeting on May 19, 2025, to review several proposals including the 2024 Board of Directors' report, Supervisory Board report, annual report, financial settlement report, profit distribution plan, and other business matters [1][3] - The company plans to conduct forward foreign exchange trading with a total annual amount not exceeding 35 million USD and will seek a comprehensive credit facility from financial institutions not exceeding 200 million RMB [2][3] - The company intends to reappoint Tianjian Accounting Firm for the 2025 financial audit and internal control audit [2][3] Performance Disclosure Highlights - In 2024, Zhendemedical achieved an operating income of 4.264 billion yuan, representing a year-on-year growth of 3.32%, while the net profit attributable to the parent company was 385 million yuan, showing a significant year-on-year increase of 94.14% [1][3] - The company plans to distribute a cash dividend of 6.50 yuan (including tax) for every 10 shares, totaling 173.11 million yuan (including tax) [1][3]

截至2025年4月25日收盘，万东医疗（600055）报收于17.58元，较上周的17.14元上涨2.57%。本周，万 东医疗4月23日盘中最高价报17.88元。4月21日盘中最低价报17.03元。万东医疗当前最新总市值123.6亿 元，在医疗器械板块市值排名19/124，在两市A股市值排名1244/5149。 本周关注点 股本股东变化 业绩披露要点 万东医疗2025年一季报显示，公司主营收入3.73亿元，同比上升21.0%；归母净利润3505.22万元，同比 上升5.4%；扣非净利润2326.89万元，同比下降25.77%；负债率8.98%，投资收益-4.88万元，财务费 用-1387.2万元，毛利率37.75%。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构 成投资建议。 股本股东变化：截至2025年3月31日公司股东户数为3.04万户，较2月28日增加397.0户 业绩披露要点：万东医疗2025年一季报显示，公司主营收入3.73亿元，同比上升21.0% 近日万东医疗披露，截至2025年3月31日公司股东户数为3.04万户，较2月28日增加 ...